SES
8.6.2020 08:52:12 CEST | Business Wire | Press release
Local residents, businesses, government entities and the San Rafael de Leticia Hospital in the Colombian Amazonas are experiencing efficient, reliable and high-performing Internet connectivity as Colombian services provider SkyNet and SES Networks extended their partnership and increased network capacity within days to support COVID-19 mitigation efforts. SkyNet leveraged SES Networks’ Signature Solutions to deliver connectivity services to the Colombian region with the highest COVID-19 infection rate and lowest internet penetration in the country, SES announced today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200607005067/en/
The Colombian Ministry of Telecommunications (MinTIC) selected SkyNet to install, operate and maintain five free Wi-Fi hotspots in Leticia to connect residents, as well as a high -speed dedicated broadband service for the local hospital’s medical and administrative teams to carry out telemedicine sessions and other eHealth activities to effectively respond to the crisis. These services are enabled by SES’s unique low-latency high-throughput O3b medium earth orbit (MEO) satellite constellation , which delivers fibre-equivalent performance to support high-performance data networks and solutions – including cloud services and applications.
According to the MinTIC, the enhanced broadband connectivity service allows local medical staff to communicate with other health professionals in Colombia’s capital Bogotá or institutions around the world. They benefit from tele-consultation services, collaboration with remote teams for faster speed to diagnosis, treatments and follow-ups for patients in the area.
SkyNet has been leveraging SES’s O3b MEO services since 2015 to connect remote Colombian regions, when they first delivered high-speed internet access and fibre-like services in Leticia empowering the local community, businesses and tourism industry. Today, SkyNet has become the incumbent provider in the area delivering reliable connectivity services to hundreds of households and businesses in Leticia, while also enabling access to e-learning platforms for a significant number of local students who cannot travel to attend classes due to the impact of COVID-19.
Additionally, SkyNet is now also leveraging the geostationary SES-14 satellite to enable one Wi-Fi zone for residents, local business and the municipal mayor´s office in Puerto Nariño. This Wi-Fi zone is the local residents’ only way to connect to the Internet as their 2G mobile coverage does not support mobile broadband connectivity.
“Our responsibility and commitment is to have a Colombia that is Naturally Connected. We return to our project in the Amazonas where since 2015 we have linked Leticia’s population to the world helping promote tourism, the main source of income for its inhabitants,” said Diego Moreno Lugo CEO of SkyNet of Colombia. “Today, information and communication technologies bring access to education, remote work and even telemedicine, and it is evident that with the health crisis of COVID-19, remote Colombian regions are worst-hit due to the lack of connectivity. The O3b service experience we are giving is very close to fibre optics and it is the best answer in satellite technology today. It brings great social impact, since it expands opportunities for education and health, and it has been without a doubt a great advancement for this entire community. As a company, we are proud to connect those sometimes-forgotten places.”
“The COVID-19 crisis has impacted us all and we’re committed to doing our part to support our customers and the local communities they serve wherever possible,” said Omar Trujillo, Vice President of Sales for Fixed Data Americas at SES Networks. “By enabling SkyNet to deliver reliable, high-speed broadband connectivity to historically underserved communities, businesses and healthcare workers in the Amazon region when they need it most is extremely gratifying. We are glad that our services are keeping loved ones connected and enabling healthcare workers with tools that empower them to do their job.”
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About SkyNet de Colombia
SkyNet is a Colombian company with more than 20 years in the satellite telecommunications market. SkyNet creates solutions that help customers grow, even in the most remote places in the country; enabling them with the widest spectrum of satellite solutions, based on its own technology and also on services from world-leading providers.
By 2020 SkyNet has established as a priority to have a country where everyone is 'Naturally Connected', consolidating its portfolio with the development of the different Bands of services, an electromagnetic spectrum frequency used in satellite communications that implements more capacity, better coverage and affordable prices. More information: https://www.sky.net.co/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200607005067/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom